IL146872A0 - Methods and compositions for modulating cell proliferation and cell death - Google Patents

Methods and compositions for modulating cell proliferation and cell death

Info

Publication number
IL146872A0
IL146872A0 IL14687200A IL14687200A IL146872A0 IL 146872 A0 IL146872 A0 IL 146872A0 IL 14687200 A IL14687200 A IL 14687200A IL 14687200 A IL14687200 A IL 14687200A IL 146872 A0 IL146872 A0 IL 146872A0
Authority
IL
Israel
Prior art keywords
compositions
methods
modulating
cell proliferation
cell death
Prior art date
Application number
IL14687200A
Other languages
English (en)
Inventor
Jessie L S Au
Guillaume M Wientjes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL146872A0 publication Critical patent/IL146872A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
IL14687200A 1999-06-03 2000-06-05 Methods and compositions for modulating cell proliferation and cell death IL146872A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13734599P 1999-06-03 1999-06-03
US16598399P 1999-11-17 1999-11-17
US17203199P 1999-12-23 1999-12-23
US18744500P 2000-03-07 2000-03-07
PCT/US2000/040103 WO2000074634A2 (en) 1999-06-03 2000-06-05 Methods and compositions for modulating cell proliferation and cell death

Publications (1)

Publication Number Publication Date
IL146872A0 true IL146872A0 (en) 2002-08-14

Family

ID=27495263

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14687200A IL146872A0 (en) 1999-06-03 2000-06-05 Methods and compositions for modulating cell proliferation and cell death
IL146872A IL146872A (en) 1999-06-03 2001-12-02 Use of cytotoxic substance and surmin for the preparation of a medicinal product

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146872A IL146872A (en) 1999-06-03 2001-12-02 Use of cytotoxic substance and surmin for the preparation of a medicinal product

Country Status (8)

Country Link
US (2) US6599912B1 (ko)
EP (1) EP1206234A4 (ko)
JP (1) JP2003503313A (ko)
KR (1) KR100903243B1 (ko)
AU (1) AU780454B2 (ko)
CA (1) CA2377385A1 (ko)
IL (2) IL146872A0 (ko)
WO (1) WO2000074634A2 (ko)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
AU5345901A (en) * 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
US6436913B1 (en) * 2000-07-25 2002-08-20 Pharmacia & Upjohn Company Use of estramustine phosphate in the treatment of bone metastasis
EP1372724A2 (en) * 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
EP1424898A4 (en) * 2001-08-20 2008-04-02 Transave Inc TREATMENT OF CANCER BY INHALATION OF STABLE FORMULATIONS CONTAINING PLATINUM
AU2002323266B2 (en) * 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
JP2005508322A (ja) * 2001-09-24 2005-03-31 ジェシー エル エス オウ 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
WO2003028696A2 (en) * 2001-10-03 2003-04-10 Celator Technologies Inc. Compositions for delivery of drug combinations
EP3020413A1 (en) 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
WO2003075890A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
BRPI0313191A2 (pt) * 2002-08-02 2016-11-08 Transave Inc composição e processo para produzir um agregado de platina e formulação farmacêutica
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
JP5118302B2 (ja) * 2002-10-29 2013-01-16 トランセイブ， インク． 抗感染剤の徐放
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US20070173466A1 (en) * 2003-03-19 2007-07-26 Katsuo Sueishi Methods of treating inflammatory diseases associated with bone destruction
JP2006524678A (ja) * 2003-04-28 2006-11-02 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 耐性乳癌の治療のためのイリノテカンの使用
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
JP2007522243A (ja) * 2004-02-13 2007-08-09 ボストン・バイオメデイカル・リサーチ・インステイテユート Ｆｇｆシグナリングの阻害
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
CN101001633A (zh) * 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
EP2471922A1 (en) * 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
AU2005265067B2 (en) * 2004-06-18 2010-12-16 Genentech, Inc. Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
RO121676B1 (ro) * 2004-08-18 2008-02-28 Institutul Oncologic "Prof.Dr. Al. Trestioreanu" Metodă de creştere a toleranţei organismului la tratamentul cu citostatice
CA2584673A1 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2008073922A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
EP2322616A1 (en) 2004-11-12 2011-05-18 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US8999706B2 (en) * 2005-04-12 2015-04-07 The Trustees Of The University Of Pennsylvania Methods for preparation of human hair-follicle derived multipotent adult stem cells
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
JP2009504751A (ja) * 2005-08-19 2009-02-05 アメリカ合衆国 ヒストンデアセチラーゼ阻害薬の局所製剤及びその使用方法
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
WO2007065016A2 (en) * 2005-12-02 2007-06-07 Au Jessie L S Methods and compositions to improve activity and reduce toxicity of stents
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US20070197599A1 (en) * 2006-02-02 2007-08-23 Matier William L Hydroxylamines and derivatives as anti-angiogenic agents
WO2008036776A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20090131348A1 (en) * 2006-09-19 2009-05-21 Emmanuel Labourier Micrornas differentially expressed in pancreatic diseases and uses thereof
US20080085881A1 (en) * 2006-10-06 2008-04-10 Aimery De Gramont Stop-and-go oxaliplatin treatment regimens
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20100196455A1 (en) * 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
JP2010529966A (ja) * 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
WO2008156644A2 (en) * 2007-06-14 2008-12-24 Frank David A Stat modulators
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090263803A1 (en) * 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2009155504A2 (en) * 2008-06-20 2009-12-23 The Children's Medical Center Corporation Methods for the modulation of angiogenesis
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
KR101289062B1 (ko) * 2009-06-01 2013-07-22 (주)차바이오앤디오스텍 인태반 유래 성장인자 및 사이토카인들을 함유한 유사 인태반 조성물 및 이의 화장품 용도
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US8445517B2 (en) 2009-12-11 2013-05-21 Dana-Farber Cancer Institute Stat modulators
EP2637672B1 (en) 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
WO2012116328A2 (en) 2011-02-24 2012-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bad phosphorylation determines ovarian cancer chemo-sensitivity and patient survival
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
EP2776043B1 (en) * 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
US9902952B2 (en) 2012-06-22 2018-02-27 Gentrum S.R.L. Euglobulin-based method for determining the biological activity of defibrotide
EP2873674B1 (en) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
JP2015530387A (ja) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー 脂質複合体化シスプラチンによる肺癌の再発防止
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
WO2014124412A2 (en) * 2013-02-11 2014-08-14 President And Fellows Of Harvard College Methods and compounds for the inhibition of cellular proliferation
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
EP3072969A1 (en) * 2015-03-23 2016-09-28 DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
BR112018000054A2 (pt) 2015-07-02 2018-09-04 Otsuka Pharmaceutical Co., Ltd. composições farmacêuticas liofilizadas
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11202000932XA (en) 2017-08-03 2020-02-27 Otsuka Pharma Co Ltd Drug compound and purification methods thereof
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252718A (en) * 1986-04-22 1993-10-12 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
US5102870A (en) 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
JPH04224522A (ja) 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
US5486509A (en) 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5587368A (en) * 1993-11-30 1996-12-24 New York University Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5574026A (en) * 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5597830A (en) 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
JPH1149701A (ja) * 1997-08-04 1999-02-23 Toagosei Co Ltd 抗癌剤
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
EP1087785A2 (en) 1998-06-15 2001-04-04 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors

Also Published As

Publication number Publication date
EP1206234A4 (en) 2005-06-01
US6599912B1 (en) 2003-07-29
CA2377385A1 (en) 2000-12-14
IL146872A (en) 2006-10-31
JP2003503313A (ja) 2003-01-28
KR20020019924A (ko) 2002-03-13
KR100903243B1 (ko) 2009-06-17
US20040010001A1 (en) 2004-01-15
EP1206234A2 (en) 2002-05-22
AU5790300A (en) 2000-12-28
WO2000074634A3 (en) 2001-08-23
AU780454B2 (en) 2005-03-24
US7625860B2 (en) 2009-12-01
WO2000074634A2 (en) 2000-12-14
WO2000074634A9 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
IL146872A0 (en) Methods and compositions for modulating cell proliferation and cell death
EP0971723A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING CELL PROLIFERATION
EP1061800A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION
HK1045299B (zh) 細胞增殖抑制劑
AU3731400A (en) Methods and compositions useful in inhibiting apoptosis
AU2548699A (en) Cell death inhibitors
IL145891A0 (en) Methods and compositions for modulating an immune response
AU3246100A (en) Methods and compositions for inhibiting neoplastic cell growth
PL337331A1 (en) Cyanoguanidines as cell proliferation inhibitors
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
HUP0003012A3 (en) Composition and method for regulating cell proliferation and cell death
AU2327700A (en) Pyrrole derivatives and cell death inhibitors
HK1039116A1 (zh) 用作細胞增殖抑制劑的氰基胍化合物
EP1231830A4 (en) COMPOSITIONS AND METHOD FOR MODULATING THE VEGETABLE CELL PARTITION
GB0318107D0 (en) ›-Secretase enzyme compositions and methods
IL140574A0 (en) Methods and compositions for modulating spermatogenesis
AU2215300A (en) Methods and compositions for inhibiting neoplastic cell growth
AU1598600A (en) Compositions and methods for modulating expression within smooth muscle cells
EP1156819A4 (en) METHODS AND COMPOSITIONS FOR REGULATING FERTILITY
AU6627800A (en) Methods and compositions for modulating somatolactogenic functions
EP1328298A4 (en) Methods and Compositions for Modulating T Cell Activation and Application
AU5931300A (en) Ringene compositions and methods for use thereof
AU5466500A (en) Methods and compositions for modulating drug activity through telomere damage
AU2399300A (en) Methods and compositions for inhibiting neoplastic cell growth
AU1631399A (en) Methods and compositions for inhibiting tumor cell growth

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed